Tesamorelin

Drug Profile

Tesamorelin

Alternative Names: EGRIFTA; Tesamorelin acetate; TH-9507; ThGRF 1-44

Latest Information Update: 25 May 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Theratechnologies
  • Developer National Heart, Lung and Blood Institute; National Institute on Aging; Theratechnologies
  • Class Pituitary hormone releasing hormones
  • Mechanism of Action Growth hormone releasing factor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Lipodystrophy
  • Phase II Mild cognitive impairment; Non-alcoholic steatohepatitis
  • Discontinued Insomnia; Lipid metabolism disorders; Muscular atrophy

Most Recent Events

  • 15 Dec 2016 Biomarkers information updated
  • 01 Sep 2016 Tesamorelin licensed to Praxis Pharmaceuticals in Spain and Portugal for commercialisation and distribution for the treatment of HIV-associated Lypodystrophy
  • 01 Sep 2016 Tesamorelin is available on a Named Patient Sales Programme for the treatment of Lipodystrophy (HIV associated) in Spain and Portugal
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top